A common genetic mutation found in clear cell renal cell carcinoma (CC-RCC) is the loss of the von Hippel-Lindau (VHL) gene, which results in stabilization of hypoxia-inducible factors (HIFs), and contributes to cancer progression and metastasis. CUB-domain-containing protein 1 (CDCP1) was shown to promote metastasis in scirrhous and lung adenocarcinomas as well as in prostate cancer. In this study, we established a molecular mechanism linking VHL loss to induction of the CDCP1 gene through the HIF-1/2 pathway in renal cancer. Also, we report that Fyn, which forms a complex with CDCP1 and mediates its signaling to PKCδ, is a HIF-1 target gene. Mechanistically, we found that CDCP1 specifically regulates phosphorylation of PKCδ, but not of focal adhesion kinase or Crk-associated substrate. Signal transduction from CDCP1 to PKCδ leads to its activation, increasing migration of CC-RCC. Furthermore, patient survival can be stratified by CDCP1 expression at the cell surface of the tumor. Taken together, our data indicates that CDCP1 protein might serve as a therapeutic target for CC-RCC.
A common genetic mutation found in clear cell renal cell carcinoma (CC-RCC) is the loss of the von Hippel-Lindau (VHL) gene, which results in stabilization of hypoxia-inducible factors (HIFs), and contributes to cancer progression and metastasis. CUB-domain-containing protein 1 (CDCP1) was shown to promote metastasis in scirrhous and lung adenocarcinomas as well as in prostate cancer. In this study, we established a molecular mechanism linking VHL loss to induction of the CDCP1 gene through the HIF-1/2 pathway in renal cancer. Also, we report that Fyn, which forms a complex with CDCP1 and mediates its signaling to PKCδ, is a HIF-1 target gene. Mechanistically, we found that CDCP1 specifically regulates phosphorylation of PKCδ, but not of focal adhesion kinase or Crk-associated substrate. Signal transduction from CDCP1 to PKCδ leads to its activation, increasing migration of CC-RCC. Furthermore, patient survival can be stratified by CDCP1 expression at the cell surface of the tumor. Taken together, our data indicates that CDCP1 protein might serve as a therapeutic target for CC-RCC. K idney cancer is the third most common malignancy of the genitourinary system and is the sixth leading cause of cancer death in the United States. Clear cell renal cell carcinoma (CC-RCC) is the most common type of kidney cancer and is increasing in number in the United States, accounting for >8 of 10 cases. Standard means for treating most solid tumors, including radioand chemotherapy, have consistently shown disappointing results in the treatment of CC-RCC, placing it among the most radio-and chemo-resistant cancers. Surgery is the primary treatment of choice for patients diagnosed with early stages of the disease. However, >30% of patients are diagnosed with metastatic disease, and one-third of initially metastasis-free patients develop metastasis after the initial surgery. No curative therapy exists for patients diagnosed with metastatic CC-RCC.
It is known that hypoxic tumor cells are especially aggressive, metastatic, and resistant to therapy (1) . Hypoxia triggers activity of hypoxia-inducible factor (HIF) that regulates expression of a large number of target genes involved in tumor progression (2) . In the presence of oxygen, HIF-1α and HIF-2α are hydroxylated on prolines 402/564 and 405/531, respectively, and are recognized by the von Hippel-Lindau tumor suppressor protein (pVHL), which mediates their degradation. Under hypoxic conditions, hydroxylation of HIF-1α and HIF-2α, and binding to pVHL decreases, HIF-1α and HIF-2α become stabilized, and each forms a heterodimer with aryl hydrocarbon receptor nuclear translocator (ARNT) to increase the expression of a large number of target genes involved in glycolysis, adhesion, migration, and angiogenesis (2, 3) . The mechanisms underlying the metastatic properties of hypoxic cells have started to emerge in the last decade (4) (5) (6) . Nevertheless, elucidation of hypoxia-regulated genes implicated in metastasis is extremely important to provide new therapeutic targets and overcome potential complications related to drug resistance.
CUB-domain-containing protein 1 (CDCP1) was first described as being expressed on the cell surface of metastatic cell lines (7).
Later, CDCP1 was shown to increase the number of nodules formed by lung adenocarcinoma cells in lungs in tail vein injection experiments (8) , enhance peritoneal dissemination of scirrhous adenocarcinoma (9) , and to induce metastasis in the chicken embryo metastatic model (10) . Although the role of CDCP1 in metastasis and its downstream signaling became the subject of investigation, the mechanism of its overexpression in multiple types of cancer was not explored. In this study, we established that the CDCP1 gene is regulated by HIF-1 and HIF-2, providing a mechanism of CDCP1 overexpression in cell types, where HIF activity is stimulated by dysregulation of signaling pathways upstream of HIF, such as isocitrate dehydrogenase 1 (IDH1), phosphoinositide 3-kinase/Akt (PI-3K/Akt), mitogen-activated protein kinase (MAPK), and Von Hippel Lindau (VHL) pathways (11) .
In this work, we investigated the role of CDCP1 in CC-RCC type of cancer, where VHL tumor suppressor gene is inactive in 80% of cases (2), leading to HIF stabilization under normoxic conditions as well as the expression of HIF target genes, including CDCP1. We further found that CDCP1 is heavily tyrosine phosphorylated in CC-RCC, is in a complex with Src family kinases (SFKs) and mediates signal transduction from SFKs to PKCδ, but not to other SFK substrates, like focal adhesion kinase (FAK) and Crk-associated substrate (CAS). Our additional findings show that Fyn is a HIF-1 target gene and PKCδ relocalizes to the cell membrane upon VHL loss, placing CDCP1 in a context for being constitutively active in CC-RCC. The metastatic process is known to manifest in increased cell motility and resistance to apoptosis in vitro. Thus, in this work we have investigated the promigratory role of CDCP1 in CC-RCC. Interestingly, we did not find a role for CDCP1 in protecting cells from anoikis in CC-RCC unlike published studies have reported for lung adenocarcinoma and scirrhous adenocarcinoma (8, 9) . However, we did find a correlation of CDCP1 cell surface expression with patient outcome: 50% of patients positive for CDCP1 on the membrane die by 90 mo of the followup; >75% of patients with negative or cytoplasmic CDCP1 are alive at the end of the followup, which is 119 mo. Thus, our data suggest that CDCP1 expression might play a crucial role in (12) . We found that CDCP1 mRNA was increased with VHL loss (RCC4 vs. RCC-VHL cells), and CDCP1 expression was induced at least threefold upon hypoxic exposure of RCC4-VHL (Fig. S1 ). We confirmed that CDCP1 mRNA was robustly induced by hypoxic exposure of RCC4-VHL cells (Fig. 1A) . Additionally, we show that CDCP1 protein is induced upon hypoxic exposure (0.5% O 2 ) in kidney cancer cells with WT VHL (ACHN, SN12C, and Caki-1) (Fig. 1B) , although SN12C and Caki-1 have considerable expression under normoxic conditions. Next, we screened for CDCP1 expression in a variety of CC-RCC cell lines, which are characterized by the VHL loss and matching cell lines where VHL was reexpressed by stable transfection. Fig. 1C shows that CDCP1 expression depends on VHL status and, accordingly, correlates with HIF expression.
Knowing that CDCP1 expression increases upon VHL loss, we hypothesized that CDCP1 would be overexpressed in CC-RCC cell lines. Microarray data available in the oncomine database comparing eight renal tumor cell lines to pooled tumor cell lines of different origin support this hypothesis by showing the highest level of CDCP1 expression in cell lines derived from kidney cancer (Fig. 1D ).
CDCP1 Expression Is Regulated by HIF-1 and HIF-2. We hypothesized that CDCP1 gene expression might be induced by HIF, based on the fact that hypoxic exposure results in activation of HIF (2, 13) and VHL loss leads to the stabilization of HIF (14, 15) . To address this hypothesis, we decided to elucidate whether CDCP1 is a target gene for HIF-1α, HIF-2α, or both. Although HIF-1α and HIF-2α have largely overlapping sets of target genes, growing evidence indicates that these two transcription factors also activate distinct hypoxia-inducible genes (16, 17) . We transiently transfected RCC4 cells, which have lost VHL expression and have both HIF-1α and HIF-2α stabilized under normoxia, with siRNAs targeting HIF-1α, HIF-2α, both HIF-1α and HIF-2α, ARNT, or scrambled siRNA. Being a common subunit in HIF-1α and HIF-2α transcriptional complexes, ARNT down-regulation by siRNA was used to inactivate both HIF-1α and HIF-2α (18) . Quantitative RT-PCR (QRT-PCR) analysis showed that the appropriate target gene expression was significantly down-regulated in these cells after siRNA transduction (Fig. S2A) ; phosphoglycerate kinase 1 (PGK1) gene expression (a known HIF-1 target; refs. 16 and 17) was abrogated when HIF-1α, both HIF-1α and HIF-2α, or ARNT were down-regulated ( Fig. 2A, i) ; CDCP1 gene expression in VHL-deficient cells was significantly inhibited when siRNAs to HIF-1α or HIF-2α were used, and was inhibited to a larger extent when siRNAs to both HIF-1α and HIF-2α, or ARNT were used, showing that CDCP1 is a target of both HIF-1 and HIF-2 ( Fig. 2A , ii). These results were confirmed in a similar experiment done with RCC4-VHL cells, which were exposed to 21% O 2 or 0.5% O 2 for 16 h ( Although CDCP1 is overexpressed in CC-RCC, the important question of whether CDCP1 signaling is active in the CC-RCC context remains. CDCP1 is a phospho-protein that has multiple tyrosine (Tyr) residues in its intracellular domain and is a substrate of Src family kinases (SFKs) (8, 19, 20) . Fyn and Yes, members of the Src family, have been reported to be in a complex with CDCP1 and promote its phosphorylation, potentiating its downstream signaling (8, 20) . Our immunoprecipitation experiments in RCC4 cells showed that CDCP1 is tyrosine-phosphorylated and is complexed with all three SFKs: Src, Fyn, and Yes in CC-RCC (Fig. 3A) .
Interestingly, Fyn kinase expression at the mRNA level was upregulated in CC-RCC tumor samples characterized by VHL loss when compared with a set of CC-RCC samples with WT VHL in microarray analysis conducted by Gordan et al. (21) . Additionally, the oncomine database shows that Fyn mRNA expression is upregulated in CC-RCC compared with other types of kidney cancer and normal kidney tissue (Fig. S3) . Despite the correlation of Fyn mRNA expression with VHL status, the causal relationship between VHL loss and Fyn up-regulation has not been explored. We established a mechanistic link between VHL and Fyn by examining changes in mRNA (Fig. 3B) and protein (Fig. 3C ) expressions in CC-RCC cell lines, which are characterized by VHL loss, and matching cell lines where the VHL was reexpressed. Indeed, VHL loss leads to up-regulation of Fyn. We did not see regulation of Yes by VHL loss. At the same time, we saw that Src is rather downregulated upon VHL loss. Those observations bring us to a conclusion that VHL loss causes the change in the ratio of SFKs in the pool. The investigation of the HIF dependence of Fyn expression leads us to conclude that Fyn is a HIF-1 target gene, because inhibition of HIF-2α had no effect on Fyn expression (Fig. 3D) . Thus, we have shown that VHL loss leads to the up-regulation of two proteins (CDCP1 and Fyn) in the triple complex, which contains CDCP1, Fyn, and PKCδ.
Several groups have demonstrated the key role of CDCP1 in transducing signal to PKCδ, supporting its phosphorylation on Tyr 311 by SFKs (8, 19) . We infected 786-0 cells with lentiviruses expressing shRNAs targeting CDCP1 or green fluorescent protein (GFP, control) and acquired stable cell lines, which we analyzed by Western blot for PKCδ phosphorylation (Fig. 4 A and B) . Tyr 311 phosphorylation of PKCδ gets ablated when CDCP1 expression is down-regulated by shRNA in the 786-0 cell line (Fig. 4B) , showing that the same signaling pathway as reported for lung adenocarcinoma and scirrhous adenocarcinoma is active in kidney cancer.
The specificity of CDCP1 shRNA action on PKCδ phosphorylation was confirmed by using independent siRNA pool targeting a different region of CDCP1 mRNA (Fig. S4) . FAK is another molecule known to be downstream of SFKs and has been reported to associate with Src and Fyn (22, 23) . Importantly, FAK phosphorylation at multiple sites did not change in response to CDCP1 down-regulation (Fig. 4C) . In addition, the phosphorylation of another SFK substrate Crk-associated substrate (CAS) (24, 25) , at Tyr 165 and Tyr 249 , was found to be CDCP1-independent in RCC4 cells (Fig. 4D) . This result reinforces the specificity in CDCP1 signal transduction from SFKs to PKCδ.
An interesting twist of PKCδ signaling, particularly in kidney cancer, comes from the link of PKCδ with pVHL. The pVHL protein was reported to directly interact with PKCδ, leading to its retention in cytoplasm and blocking the association between PKCδ and the IGF-I receptor for downstream signaling (26, 27) . Our immunofluorescence study of PKCδ and CDCP1 localization in RCC4 and RCC4-VHL cells shows that CDCP1 is localized on the membrane and in the cytoplasm of RCC4 cells, and the staining intensity in RCC4-VHL cells is much lower compared with RCC4 (Fig. S5) . PKCδ localizes mainly in the nucleus in both cell lines. However, we detected PKCδ on the membrane, colocalizing with CDCP1, in RCC4 cells, but not in RCC4-VHL cells. Thus, VHL loss might be of particular importance for stimulation of PKCδ signaling leading to PKCδ translocation to the membrane as well as CDCP1 and Fyn up-regulation and subsequent PKCδ phosphorylation at Tyr 311 .
CDCP1 Signaling Pathway Promotes Migration of CC-RCC.
To address the mechanism of CDCP1 action in CC-RCC, we investigated a number of different biological endpoints. We sought to determine whether CDCP1 might be involved in apoptosis, cell adhesion, migration, epithelial-mesenchymal transition (EMT), and cell growth based on the known properties of metastatic cells (8-10, 20, 28, 29). Cell migration is important for the cancer cells to spread beyond the primary tumor site because cells need to intravasate into blood vessels, then extravasate from them and colonize a distant organ. We assessed the migratory capacity of a number of CC-RCC cell lines in transwells, including 786-0, RCC4, RCC10, and UMRC6, and 786-0 cells proved to be the most suitable for this in vitro assay (Fig. S6) . We compared the amount of migrated cells through transwells coated with fibronectin by using shGFPinfected and shCDCP1-infected 786-0 cells. We observed a 40% reduction in migratory ability of 786-0 cells when CDCP1 was down-regulated (Fig. 5A) .
At the same time, our experiments showed no involvement of CDCP1 into apoptosis in suspension (anoikis) [no difference in soft agar growth (Fig. S7A) ; colony formation on culture dishes (Fig.  S7B) ; Caspase 3 cleavage after incubation on low-adhesion plates (Fig. S7C) ], EMT [no changes in classic EMT markers such as Ncadherin, Lysyl oxidase (LOX), and Snail1 as juged by QRT-PCR (Fig. S7D) ; and Western blot for N-cadherin (Fig. S7E) ], cell growth (Fig. S7F) , and cell adhesion [no difference in adhesion to fibronectin, fibrinogen, collagen I and IV, except increased adhesion to laminin when CDCP1 was down-regulated in 786-0 cells (Fig. S7G) ].
CDCP1 Promotes CC-RCC Migration Through PKCδ Activation. Our data indicate that CDCP1 is absolutely necessary for signal transduction from SFKs to PKCδ Tyr 311 and not to other SFK targets. Furthermore, PKCδ was reported to induce migration of RCC (30) . To address the question whether CDCP1-mediated PKCδ signaling promotes migration of CC-RCC, we used siRNAs targeting CDCP1, PKCδ, or nontargeting control siRNA. The knockdowns were confirmed by immunoblotting (Fig. 5B, i) , and migration assays were performed 48 h after transfection (Fig. 5B,  ii) . The 786-0 cells when transiently transfected with siRNA pool targeting CDCP1 exhibited a 50% reduction in migration (Fig.  5B) . The results clearly show that PKCδ down-regulation by RNA interference leads to a 50% reduction in CC-RCC cell migration, which phenocopies the effect of CDCP1 siRNA. To further confirm the role of PKCδ in signal transduction from CDCP1 leading to enhanced migration, we rescued the reduction in migration caused by CDCP1 knockdown by overexpressing constitutively active mutant of PKCδ (R144/145A) (31) (Fig. 5C) . Those results emphasize the importance of CDCP1 in migration and provide an in vitro mechanism of CDCP1 action in CC-RCC through PKCδ activation.
CDCP1 Expression on the Cell Surface of Tumor Cells Correlates with
the Poor Survival of Patients Diagnosed with Kidney Cancer. Four studies assessed the possibility of using the level of CDCP1 expression as a prognostic factor for survival of lung adenocarcinoma, conventional RCC, pancreatic cancer patients, and endometrioid adenocarcinoma (29, (32) (33) (34) . All of them indicated that elevated CDCP1 expression correlates with low overall survival. We used an antibody that recognizes the extracellular domain of CDCP1 (R&D Systems) and stained a kidney cancer tissue microarray (TMA), which contains 50 kidney cancer tissue cores, most of the primary tumor origin. The specificity of the antibody was confirmed by immunoblotting of 786-0 cells transduced with shRNAs to CDCP1 or GFP (Fig. S8) . Sixty-seven percent of samples had membrane and/or cytoplasmic staining of CDCP1, and 29% of samples had membrane staining only. Representative pictures of tumors scored as negative (i), positive cytoplasmic (ii), and positive membrane (iii) are shown in Fig. 6A . This TMA was accompanied with patient survival data, and we conducted Kaplan-Meier survival analysis of kidney cancer patients based on CDCP1 staining. In this analysis, group one represents patients totally negative for CDCP1 staining pooled with the patients with CDCP1 staining in the cytoplasm, whereas group two consists of patients with CDCP1 staining on the membrane. By this analysis, the survival curves are statistically significant with a P value of 0.0163. The median survival for patients with CDCP1 staining on the membrane is 90 mo (Fig. 6B ).
Discussion
Our data show that CDCP1 is a downstream target of HIFs and plays a critical role in kidney cancer migration (Fig. 7) . Importantly, VHL loss, which occurs in 80% of CC-RCC kidney cancer cases, results in HIF-dependent CDCP1-mediated signaling to PKCδ, leading to PKCδ translocation to the membrane and subsequent PKCδ phosphorylation at Tyr 311 , which manifests in increased migration. We assume that CDCP1 gene regulation can be induced by HIF via (i) direct binding and activation of the CDCP1 gene promoter, or (ii) indirect activation of CDCP1 transcription through a HIF-dependent pathway. The analysis of the CDCP1 promoter region and the first intron showed that there are multiple HIF consensus binding sites. Further studies are needed to define the putative HIF binding site within CDCP1 promoter.
Although there are multiple tyrosine phosphorylation sites on PKCδ, Tyr 311 located between the regulatory and catalytic domains has been linked to increased kinase activity in cells treated with H 2 O 2 (35, 36) . Experiments from a number of laboratories now support the idea that PKCδ is a positive regulator of breast cancer growth and metastasis (37) (38) (39) (40) and promotes cell survival and chemotherapeutic resistance of nonsmall cell lung cancer cells (41) . PKCδ has also been reported to induce migration of RCC, prostate cancer, and pancreatic cancer cells through poorly elucidated mechanism (29, 30) . Signal transduction from CDCP1 to PKCδ Tyr 311 was described in several cancer cell types (8, 19, 29) , and was linked to anoikis in A549 (8) and to cell migration in BxPC3 and Capan1 cells (29) , but the direct evidence of the PKCδ involvement in those processes has not been demonstrated. Our study provides a direct link between CDCP1 and migration through activation of PKCδ in CC-RCC, showing that the reduction in migration in the absence of CDCP1 can be rescued by overexpression of constitutively active PKCδ mutant. At the same time, we did not find any role of CDCP1 in protecting CC-RCC from anoikis, which can be explained by multiple redundant apoptosis resistance mechanisms in play in CC-RCC, activated as a result of HIF stabilization upon VHL loss.
In this study, we have demonstrated the possibility of using cell surface CDCP1 expression as a prognostic factor for survival of kidney cancer patients. Interestingly, CDCP1 localization was heterogeneous in the TMA, CDCP1 was localized in the cytoplasm, or cell membrane, or both cytoplasm and cell membrane. Surprisingly, 67% of specimens were CDCP1-positive, but just 29% had cell surface expression of CDCP1. However, several kidney cancer cell lines analyzed by fluorescence-activated cell sorting (786-0, RCC4, RCC10, UMRC6, ACHN; Fig. S9 ) have revealed the presence of CDCP1 on the cell surface. These results suggest an additional mechanism for CDCP1 regulation in vivo by changing its localization.
The data presented in this article suggest that blocking CDCP1 might be beneficial to prevent migration and, subsequently, metastatic spread. Moreover, CDCP1 expression on the cell surface of kidney cancer cells represents an ideal target for antibody-and small molecule-based therapeutics. Indeed, the antibody mAb41-2, which targets CDCP1, was reported to have antimetastatic activity toward CDCP1 overexpressing HeLa cells and PC3 cells (10) . To date, our knowledge of CDCP1 function in normal tissues is limited. Thus, generation of CDCP1 knockout mice would be important to shed light on CDCP1 function under physiologic conditions.
Methods
Hypoxic Treatment. Cells were plated in glass dishes 12-24 h before hypoxic treatment and subjected to hypoxia in chambers [Invivo 2 400 Hypoxic workstation (0.5%), Biotrace]. For Western blot analysis, cells were lysed inside the chamber.
Cell Transfections with siRNAs. Cells were transfected with nontargeting siControl#1, #2, or siControl pool, siHIF-1α, siHIF-2α, siARNT, siCDCP1, and siPKCδ smart pools (Dharmacon) by using Dharmafect1 reagent (Dharmacon) according to manufacturer's instructions.
Migration Experiments. All migration experiments were done on cells dislodged with cell dissociation buffer (Gibco), which were allowed to migrate through fibronectin-coated transwells (Costar) for 24 h.
shRNA Expression Constructs, Lentivirus Packaging, and Infection of Target Cells. Lentiviral plasmids pLKO.1shCDCP1 (Open Biosystems) and pLKO.1shGFP, and retroviral plasmids LZRS-myc-PKCδR144/145A (31) and LZRS-linker were used for viral production as described in ref. 42 .
